Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10476942rdf:typepubmed:Citationlld:pubmed
pubmed-article:10476942lifeskim:mentionsumls-concept:C1257890lld:lifeskim
pubmed-article:10476942lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:10476942lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:10476942lifeskim:mentionsumls-concept:C0026639lld:lifeskim
pubmed-article:10476942lifeskim:mentionsumls-concept:C0002199lld:lifeskim
pubmed-article:10476942lifeskim:mentionsumls-concept:C0021747lld:lifeskim
pubmed-article:10476942lifeskim:mentionsumls-concept:C0151449lld:lifeskim
pubmed-article:10476942lifeskim:mentionsumls-concept:C1415900lld:lifeskim
pubmed-article:10476942lifeskim:mentionsumls-concept:C0449444lld:lifeskim
pubmed-article:10476942lifeskim:mentionsumls-concept:C0282460lld:lifeskim
pubmed-article:10476942lifeskim:mentionsumls-concept:C0442711lld:lifeskim
pubmed-article:10476942lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:10476942lifeskim:mentionsumls-concept:C1521801lld:lifeskim
pubmed-article:10476942lifeskim:mentionsumls-concept:C0205296lld:lifeskim
pubmed-article:10476942pubmed:issue8lld:pubmed
pubmed-article:10476942pubmed:dateCreated1999-10-22lld:pubmed
pubmed-article:10476942pubmed:abstractTextThe purpose of this investigation was to examine the safety and efficacy of four dosages of natural human interferon-alpha (nHuIFN-alpha) delivered over a 12-week period orally in lozenges (150 IU and 450 IU, once [QD] or three times [TID] daily) compared to placebo in subjects with primary Sjögren's syndrome. This randomized, double-blinded clinical trial demonstrated that nHuIFN-alpha at a dose of 150 IU administered TID by oral lozenge significantly improved stimulated whole saliva output compared to placebo after 12 weeks of treatment. The 150 IU TID dose also was suggestive of benefit for 5 of 7 subjective measures of oral and ocular comfort. IFN lozenges demonstrated a good safety profile, with no serious adverse events found in any treatment group. There were no significant differences between the placebo and the four doses of IFN for adverse events by total number, organ system, severity, dropouts, and number judged to be related to treatment. In conclusion, these results demonstrated that the use of 150 IU IFN lozenges TID for 12 weeks in subjects with primary Sjögren's syndrome improved salivary output and decreased complaints of xerostomia without causing significant adverse medical events.lld:pubmed
pubmed-article:10476942pubmed:languageenglld:pubmed
pubmed-article:10476942pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10476942pubmed:citationSubsetIMlld:pubmed
pubmed-article:10476942pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10476942pubmed:statusMEDLINElld:pubmed
pubmed-article:10476942pubmed:monthAuglld:pubmed
pubmed-article:10476942pubmed:issn1079-9907lld:pubmed
pubmed-article:10476942pubmed:authorpubmed-author:FoxP CPClld:pubmed
pubmed-article:10476942pubmed:authorpubmed-author:RichardsA BABlld:pubmed
pubmed-article:10476942pubmed:authorpubmed-author:CumminsM JMJlld:pubmed
pubmed-article:10476942pubmed:authorpubmed-author:ShipJ AJAlld:pubmed
pubmed-article:10476942pubmed:authorpubmed-author:MichalekJ EJElld:pubmed
pubmed-article:10476942pubmed:issnTypePrintlld:pubmed
pubmed-article:10476942pubmed:volume19lld:pubmed
pubmed-article:10476942pubmed:ownerNLMlld:pubmed
pubmed-article:10476942pubmed:authorsCompleteYlld:pubmed
pubmed-article:10476942pubmed:pagination943-51lld:pubmed
pubmed-article:10476942pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:10476942pubmed:meshHeadingpubmed-meshheading:10476942...lld:pubmed
pubmed-article:10476942pubmed:meshHeadingpubmed-meshheading:10476942...lld:pubmed
pubmed-article:10476942pubmed:meshHeadingpubmed-meshheading:10476942...lld:pubmed
pubmed-article:10476942pubmed:meshHeadingpubmed-meshheading:10476942...lld:pubmed
pubmed-article:10476942pubmed:meshHeadingpubmed-meshheading:10476942...lld:pubmed
pubmed-article:10476942pubmed:meshHeadingpubmed-meshheading:10476942...lld:pubmed
pubmed-article:10476942pubmed:meshHeadingpubmed-meshheading:10476942...lld:pubmed
pubmed-article:10476942pubmed:meshHeadingpubmed-meshheading:10476942...lld:pubmed
pubmed-article:10476942pubmed:meshHeadingpubmed-meshheading:10476942...lld:pubmed
pubmed-article:10476942pubmed:meshHeadingpubmed-meshheading:10476942...lld:pubmed
pubmed-article:10476942pubmed:meshHeadingpubmed-meshheading:10476942...lld:pubmed
pubmed-article:10476942pubmed:meshHeadingpubmed-meshheading:10476942...lld:pubmed
pubmed-article:10476942pubmed:meshHeadingpubmed-meshheading:10476942...lld:pubmed
pubmed-article:10476942pubmed:meshHeadingpubmed-meshheading:10476942...lld:pubmed
pubmed-article:10476942pubmed:meshHeadingpubmed-meshheading:10476942...lld:pubmed
pubmed-article:10476942pubmed:year1999lld:pubmed
pubmed-article:10476942pubmed:articleTitleTreatment of primary Sjögren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group.lld:pubmed
pubmed-article:10476942pubmed:affiliationDepartment of Oral Medicine/Pathology/Oncology, University of Michigan School of Dentistry, Ann Arbor 48109-1078, USA. jship@umich.edulld:pubmed
pubmed-article:10476942pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10476942pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:10476942pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:10476942pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10476942lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10476942lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10476942lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10476942lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10476942lld:pubmed